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Abstract 
Background: Heart failure (HF) trials selecting patients based on history of HF 
hospitalization alone are susceptible to regional variation in event rates. Elevated 
natriuretic peptides (NPs) as selection criteria may help HF ascertainment and risk 
enrichment. In the COMMANDER-HF trial, B-type natriuretic peptide (BNP)≥200ng/L 
or N-terminal pro-BNP ≥800ng/L were added to inclusion criteria as a mid-trial protocol 
amendment, providing a unique case-study of NP-based inclusion criteria. 
Methods: We compared the baseline characteristics, event rates, and treatment effects for 
patients enrolled before/after NP protocol amendment. The primary endpoint was all-
cause death, myocardial infarction, or stroke. Secondary endpoints included HF 
rehospitalization and cardiovascular death.  
Results: A total of 5022 patients with LVEF ≤40% and coronary artery disease were 
included. Compared to patients enrolled before the NP protocol amendment, those 
enrolled post-amendment (n=3867, 77%) were older, and had more prevalent diabetes, 
lower BMI, LVEF and eGFR, higher heart rate and higher event rates: primary endpoint 
(HR 1.32, 95%CI 1.16-1.50), cardiovascular death (HR 1.29, 95%CI 1.11-1.50), HF 
rehospitalization (HR 1.31, 95%CI 1.15-1.49), and ISTH major bleeding (HR 1.71, 95% 
CI 1.11-2.65). Differences between pre- and post-amendment rates were confined to and 
driven by Eastern Europe. This protocol amendment did not modify the neutral effect of 
rivaroxaban on the primary endpoint (p-interaction=0.36) or secondary endpoints.  
Conclusion: In a global event-driven trial of rivaroxaban in HF, requiring elevated NPs 
for inclusion increased event rates allowing earlier completion of the trial, but did not 
modify treatment effect. These data inform future HF trials regarding the expected impact 
of NP-based inclusion criteria on patient characteristics and event rates.  
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BNP = B-type natriuretic peptide 
COMMANDER HF = A Study to Assess the Effectiveness and Safety of Rivaroxaban in 
Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart 
Failure and Coronary Artery Disease Following an Episode of Decompensated Heart 
Failure 
CI = confidence interval 
CV = cardiovascular 
HF = heart failure 
HR = hazard ratio 
ISTH = International Society on Thrombosis and Haemostasis 
LVEF = left ventricular ejection fraction 
NT-proBNP = N-terminal pro-B-type natriuretic peptide  
py = patient-years 
 
Introduction 
Careful definition of the study population is crucial for an efficient and generalizable 
clinical trial in heart failure (HF). Restricting enrollment to patients with rigorously 
defined HF who are at increased risk for endpoint events can increase the rate of events 
that are potentially modifiable, thereby increasing statistical power. Recent HF trials have 
used natriuretic peptide levels as inclusion criteria because they help to confirm the 
diagnosis of HF and are associated with increased event rates.(1-6) 
  In this analysis, we examine a case study in the effects of natriuretic peptide-
based entry criteria on the clinical profile of the patients enrolled, event rates and study 
outcomes. COMMANDER HF (A Study to Assess the Effectiveness and Safety of 
Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in 
Participants with Heart Failure and Coronary Artery Disease Following an Episode of 
Decompensated Heart Failure) was a double-blind, randomized, placebo-controlled trial 
of low-dose rivaroxaban in patients recently admitted for decompensated HF.(7,8) At the 
beginning of the trial, decompensated HF was defined based on the site investigator’s 
clinical assessment of the patient’s HF symptoms and signs. After enrollment of 23% of 
patients, and because of the observation of a lower than expected blinded (pooled for 2 
treatment groups) event rate, the protocol was amended to require N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) concentration ≥800 ng per liter (L) or B-type natriuretic 
peptide (BNP) concentration ≥200 ng/L for enrollment. The purpose of the amendment 
was to prevent further enrollment of low risk patients who had not truly been hospitalized 
for decompensated HF, and thereby increase event rates and allow for more rapid 
completion of this event-driven trial. The addition of this amendment to the entry criteria 
represents a unique opportunity to study the consequences of natriuretic peptide-based 
inclusion criteria while other inclusion criteria influencing enrollment are held constant.  
 
Methods 
Study Population & Clinical Endpoints 
The study design of the COMMANDER HF trial has been previously described.(7,8) 
COMMANDER HF was an international, double-blind, randomized trial comparing the 
factor Xa inhibitor rivaroxaban and placebo. Key inclusion criteria included history of 
chronic HF for 3 months, treatment for decompensated HF in the previous 30 days, left 
ventricular ejection fraction (LVEF) ≤40%, history of coronary artery disease, and 
absence of atrial fibrillation or other indication for chronic anti-coagulation. 
Decompensated HF was defined by symptoms of worsening dyspnea or fatigue, objective 
signs of congestion, and/or adjustment of HF medications, requiring hospital admission 
or unscheduled parenteral diuretic.  
Rivaroxaban dosed at 2.5mg twice daily did not reduce the incidence of the 
primary efficacy outcome, a composite of all-cause death, myocardial infarction, or 
stroke. Other efficacy endpoints included re-admission for worsening HF, cardiovascular 
(CV) and non-CV or unknown death, and components of the primary endpoint. 
Investigators reported outcomes on detailed case report forms, and the sponsor’s clinical 
operations team verified the events using source data.  Patients were followed until 
approximately 30 days after the global treatment end date, regardless of the date of 
enrollment. All subjects provided written informed consent. The protocol was approved 
by the appropriate institutional review board or ethics committee at each site.  
 
Natriuretic Peptide Amendment 
In May 2014, based on review of patient characteristics and the blinded event rate for 
1155 patients, the Steering Committee amended the enrollment criteria to require a 
plasma NT-proBNP level 800ng/L or BNP level 200ng/L at any time between the 
index admission for decompensated HF and randomization.(8) Natriuretic peptide levels 
were measured by the individual site and were not verified by a core lab. Simultaneous 
with the amendment, enrollment in the Asia-Pacific region and several additional 
countries began. A total of 1440 patients were in countries that enrolled only after the 
protocol amendment; 3582 patients were in countries that enrolled both before and after 
the amendment. No countries enrolled only before the amendment. 
 
Statistical Analysis 
In this analysis, we compared baseline characteristics and crude event rates per 100 
patient years for clinical outcomes in patients enrolled before and after the natriuretic 
peptide amendment. We described baseline characteristics using mean and standard 
deviation for normally distributed continuous variables, median and interquartile range 
for skewed continuous variables, and number and proportion for categorical variables. 
We compared these variables using F test, Chi-square test, Wilcoxon rank sum test, and 
Cochran-Mantel-Haenszel test as appropriate. We described time-to-first event outcomes 
using Kaplan-Meier estimates of cumulative risk and compared them between pre and 
post amendment groups using log rank test and Cox proportional hazards models with 
pre/post amendment as the only effect. The proportional hazards assumption was 
evaluated by testing for significant trend in the change of hazard ratio over time and was 
not violated. Events rates before and after the protocol amendment were compared within 
regions, and heterogeneity in amendment effect by region was assessed through the 
interaction term for region and amendment using Cox models. We performed a 
sensitivity analysis excluding the Asia Pacific region and other countries that enrolled 
only after the protocol amendment, since differences in event rates in this population 
could be due opening enrollment at new sites rather than the amendment. In a second 
sensitivity analysis, follow-up for clinical events was limited to 2 years (all patients 
censored event-free at 2 years from randomization if still at risk), to address shorter 
follow-up duration in the post-amendment group. Two years was selected as the 
maximum duration in this analysis because 75% of patients in the post-amendment group 
had been censored or experienced primary endpoint events by that time. Heterogeneity 
caused by the amendment regarding to the treatment effect of rivaroxaban was evaluated 
through the interaction term for treatment and amendment using Cox models. A 2-sided 
p-value of <0.05 was considered significant. SAS version 9.4 (Cary, North Carolina) was 




The baseline characteristics of patients enrolled after the amendment were consistent with 
greater risk. Post-amendment patients were older (67 years vs 65 years), with more 
prevalent diabetes (43% vs 34%) and anemia (34% vs 22%), higher heart rate (72 bpm vs 
69 bpm) and lower systolic blood pressure (122 mmHg vs 124 mmHg) compared to 
patients enrolled pre-amendment (Table 1). After the amendment, LVEF was lower 
(33% vs 36%), estimated glomerular filtration rate was lower (67 mL/min/1.73m2 vs 71 
mL/min/1.73m2), and D-dimer was higher (380 µg/L vs 310 µg/L) compared to before 
the amendment. Rates of neurohormonal therapy were high in both groups, but slightly 
lower after the amendment. Cardiac devices were more common after the amendment 
(14% vs 9%). Conversely, fewer patients enrolled after the amendment were New York 
Heart Association functional class III or IV (51% vs 61%). 
The regional distribution of patients shifted after the amendment. The majority of 
patients in both time periods were in Eastern Europe, but the percentage decreased from 
89% before the amendment to 57% afterwards. Following the amendment, the 
proportions of North American, Latin American, and Western European patients 
increased. Asia Pacific enrollment began at time of the amendment.  
 
Clinical Outcomes 
Rates of key efficacy endpoints increased after the natriuretic peptide amendment. The 
primary efficacy endpoint, a composite of all-cause death, myocardial infarction, and 
stroke was more common after the amendment (15.46 vs 11.22 events per 100 patient-
years[py], HR 1.32, 95% CI 1.16-1.50, p<0.001 using pre-amendment event rate as 
reference) (Central Illustration & Table 2). A higher rate of all-cause mortality (12.84 
vs 9.38 events/100py, HR 1.35, 95% CI 1.17-1.55, p<0.001) drove this difference. CV 
death (10.82 vs 7.91 events/100py, HR 1.29, 95% CI 1.11-1.50, p=0.001) and non-CV or 
unknown death (2.01 vs 1.48 events/100py, HR 1.70, 95% CI 1.18-2.45, p=0.004) were 
both more frequent after the amendment; relative risk was greater for non-CV or 
unknown death, but absolute event rates for CV death were higher. Risk of 
rehospitalization for HF increased after the amendment (20.74 vs 11.82 events/100py, 
HR 1.31, 95% CI 1.15-1.49, p<0.001).  
 The increase in primary endpoint event rate after the protocol amendment was 
driven by and confined to Eastern Europe (Table 3). Eastern European sites enrolled 89% 
of patients before the protocol amendment and 57% afterwards. Eastern Europe had the 
lowest event rate of any region both before and after the amendment. In Eastern Europe, 
the amendment increased the primary endpoint event rate by 35% (13.64 events/100py 
post-amendment vs 10.11 events/100py pre-amendment, HR 1.33, 95% CI 1.14-1.56). 
Comparison of event rates pre/post amendment in other regions was limited as >93% of 
patients in these regions were enrolled post-amendment; however, there was no signal for 
an increase in event rate. Similar regional differences in event rates were observed for 
other efficacy outcomes.  
Bleeding rates were overall low but increased after the amendment (Table 4). 
There was a trend toward increased rate of the primary safety endpoint—a composite of 
fatal bleeding or bleeding into a critical space with a potential for causing permanent 
disability—that did not reach statistical significance (0.61 vs 0.32 events/100py, HR 1.51, 
95% CI 0.71-3.20, p=0.28). International Society on Thrombosis and Haemostasis 
(ISTH) major bleeding (2.10 events/100py post-amendment vs 0.86 events/100py pre-
amendment, HR 1.71, 95% CI 1.11-2.65, p=0.02), bleeding in a critical space with 
potential permanent disability (0.56 vs 0.16 events/100py, HR 3.01, 95% CI 1.10-8.26, 
p=0.03) and ISTH bleeding at a critical site (0.84 vs 0.19 events/100py, HR 3.79, 95% CI 
1.54-9.33, p<0.01) occurred more frequently in post-amendment patients. 
 
Sensitivity Analyses 
To address the possibility that opening enrollment in Asia Pacific and other 
countries after the amendment caused the changes in event rates, we performed a 
sensitivity analysis excluding these countries (Supplemental Table 1). This sub-
population included 3582 patients: all 1155 patients enrolled pre-amendment and 2427 
patients enrolled post-amendment. A similar pattern of results was observed as in the full 
population, though with less statistical power. The increased risk of the primary efficacy 
endpoint (HR 1.23, 95% CI 1.07-1.42, p<0.01) and CV death (1.28, 95% CI 1.09-1.51, 
p<0.01) retained statistical significance in this population. The differences in non-CV or 
unknown death (HR 1.41, 95% CI 0.93-2.12, p=0.10) and rehospitalization for HF (HR 
1.10, 95% CI 0.96-1.26, p=0.19) did not reach statistical significance. Differences in 
bleeding endpoints were directionally consistent but no longer statistically significant. 
A second sensitivity analysis restricted follow-up to the first 2 years following 
randomization, in order to balance the duration of follow-up between the pre- and post-
amendment groups. Because all patients were followed until the global trial end date 
regardless of randomization date, median follow-up was longer in the pre-amendment 
group (3.6 years pre-amendment vs 1.4 years post-amendment). The results of this 
sensitivity analysis were similar to the main trial population (Supplemental Table 2).  
 
Treatment Group Interaction 
Enrollment before or after the natriuretic peptide amendment did not modify the null 
relationship between rivaroxaban and the primary efficacy endpoint (p-interaction=0.36) 
or any other endpoints (Table 5). The hazard ratio of rivaroxaban for the primary 
efficacy endpoint was 1.02 (0.84-1.24) before the amendment and 0.91 (0.80-1.04) after 
the amendment.  
 
Discussion 
In a global clinical trial of low-dose rivaroxaban in patients recently treated for 
decompensated HF with sinus rhythm, reduced LVEF, and underlying coronary artery 
disease, we studied the impact of a protocol amendment requiring elevated natriuretic 
peptide level for inclusion. This amendment was mandated by the lower than expected 
event rate after enrollment of almost 25% of the targeted number of patients, and the 
suspicion that including patients based on history of recent admission alone may have led 
to enrolling patients with heterogenous risk. The amendment resulted in (1) enrollment of 
patients with more comorbidities, (2) ~30% higher rates of the primary endpoint (death, 
MI or stroke) driven by Eastern European sites and (3) higher rates of rehospitalization 
for HF, bleeding, and death (both CV and non-CV). Despite the amendment, no 
difference in rivaroxaban treatment effect was observed. Our results support the use of 
natriuretic peptide-based inclusion criteria in future HF trials to enrich events, especially 
in trials where HF is mainly ascertained by a history of HF hospitalization. Bleeding and 
non-CV death rates should be considered when selecting natriuretic peptide thresholds, as 
higher thresholds may alter the benefit-to-harm trade-off and increase the risk for 
competing events. (9,10) 
The concordant increases in baseline risk profile and event rates were consistent 
with our hypothesis that the protocol amendment prevented a subgroup of lower risk 
patients from Eastern Europe from enrolling. Baseline factors traditionally associated 
with poor prognosis, including older age, lower LVEF, and renal dysfunction, were more 
common after the amendment. One discordant variable was site-determined New York 
Heart Association functional class, which was lower after the amendment (i.e. fewer 
patients were attributed functional class III or IV after the amendment). The distinction 
between functional classes II and III is subjective and could have been subjectively 
inflated by investigators in the pre-amendment group to justify trial enrollment. A similar 
pattern in the baseline characteristics was found in the TOPCAT trial, despite including a 
very different population; patients enrolled by natriuretic peptide-based criteria were 
older, with lower potassium and eGFR, compared to those enrolled based on 
hospitalization alone. (11) 
We chose not to control for baseline characteristics because changes in baseline 
characteristics are on the causal pathway between the inclusion criteria and events. We 
were, however, concerned that opening of enrollment in Asia Pacific and other countries 
after the amendment could have confounded our results, because patients in these areas 
have been shown to present major differences in characteristics and events compared to 
patients in other geographical areas.(12) However, a sensitivity analysis excluding these 
countries/regions showed a slightly smaller but still significant increase in event rates 
after the amendment. Moreover, regional analysis shows that a higher event rate within 
the largest region, Eastern Europe, drove the changes. It is likely that both the natriuretic 
peptide protocol amendment and addition of new regions with high event rates 
contributed to the increase in event rates. But, using the sensitivity analysis, we were able 
to isolate the distinct effect of the NP amendment. Our findings are consistent with and 
build upon prior work demonstrating that natriuretic peptides are markers of HF 
risk.(4,13) Age-based cutoffs (NT-proBNP 450, 900, and 1800 ng/L for ages <50, 50-75, 
and >75, respectively) demonstrate 90% sensitivity and 84% specificity for the diagnosis 
acute HF.(2) Once HF has been diagnosed, higher natriuretic peptide levels predict 
adverse events.(3,14) Among patients enrolled in COMMANDER HF with available 
natriuretic peptide values, patients in the highest quartile had nearly double the event rate 
of those in the lowest quartile.(8) The protocol amendment described in this study 
provides a unique case study that isolates the effect of natriuretic peptide-based inclusion 
criteria while other trial-level factors were held constant. Requiring elevated natriuretic 
peptides for enrollment enriched event rates despite a background of other high-risk 
features: recent decompensated HF, reduced LVEF, and history of coronary artery 
disease.  
The 32% increase in primary endpoint event rate after the natriuretic peptide 
protocol amendment allowed more rapid completion of this event driven trial. A total of 
1284 primary endpoint events occurred in 5022 patients during the trial. Assuming stable 
event rates over time and similar duration of follow-up, if the amendment had not been 
made, the trial would have needed to recruit an additional one thousand patients for a 
total of 6016. On the other hand, had original protocol required elevated natriuretic 
peptides, only 4366 patients would have been required. However, improved efficiency 
must be balanced against the risk of enrolling patients with more advanced disease whose 
clinical course is not modified by the study drug. Observed increases in rates of bleeding 
and non-cardiovascular death after the protocol amendment demonstrate that non-
modifiable events are also more common in patients with high natriuretic peptides. Prior 
research has found that elevated troponin identifies patients at greater risk for specifically 
CV death, while elevated NT-proBNP is associated with both CV and non-CV death 
rates. (15)  Other contemporary clinical trials in HF with reduced ejection fraction have 
adopted natriuretic peptide-based inclusion criteria, with varying cutoffs depending on 
the target population. In chronic HF, the DAPA-HF trial required NT-proBNP ≥600ng/L 
for most patients, with a lower threshold (≥400ng/L) for patients hospitalized for HF 
within 12 months and a higher threshold (≥900ng/L) for patients in atrial fibrillation.(6) 
Patients in atrial fibrillation have higher levels of NT-proBNP independent of HF 
severity.(16,17) The PIONEER-HF trial, which enrolled decompensated HF patients, 
required higher levels: NT-proBNP >1600ng/L or BNP>800ng/L.(5) In our study, a 
threshold of NT-proBNP800ng/L, though lower than average levels in decompensated 
HF which exceed 4000ng/L, was sufficient to enrich the population.(2) A lower threshold 
for obese patients could be considered since natriuretic peptide levels are lower in obese 
patients for similar HF severity. 
We found that natriuretic peptide-based inclusion criteria were particularly 
important in Eastern Europe, a region which offers rapid enrollment but has suffered 
from low event rates and inconsistent application of inclusion criteria in other HF 
trials.(18,19) The TOPCAT trial, which included patients with HF and preserved ejection 
fraction, a population in which diagnosis is more subjective, exemplifies this issue. 
Patients from Russia and Georgia were more likely to be enrolled by hospitalization 
criteria alone rather than elevated natriuretic peptide level, and experienced similar event 
rates to the general population of those countries and one quarter as many primary 
endpoint events as those in the Americas.(20) In COMMANDER HF, the large 
proportion of patients enrolling in Eastern Europe, and their low event rate, contributed to 
the decision to implement the natriuretic-peptide protocol amendment. The amendment 
likely prevented the further enrollment of Eastern European patients whose index 
hospitalization was not truly for worsening HF. Our findings demonstrate the utility of 
objective inclusion criteria such as natriuretic peptides, especially in regions where the 
patient characteristics, treatments, and access to care may be very different.  
 
Our analysis has several limitations. First, as in any study comparing outcomes before 
and after an intervention, it is possible that other changes were responsible for the 
observed differences in event rates. As described, a sensitivity analysis excluding 
countries in which enrollment opened at or after the amendment yielded consistent 
results. Second, follow-up was by necessity shorter for patients enrolled after the 
amendment, since all patients who did not experience events were censored on the global 
treatment end date of this event-driven trial. However, a sensitivity analysis in which all 
patients were censored 2 years after randomization showed consistent results. Third, 
natriuretic peptide levels were measured by the individual sites, not a core lab, which 
could have introduced inaccuracy. However, use of readily available, site-reported values 
reduces cost and avoids the need to ship samples to a central lab or provide sites with 
point of care assays. Fourth, assessment of rivaroxaban treatment benefit in appropriate 
patients enrolled after the natriuretic-peptide amendment was underpowered, since the 
power calculation was performed on the whole population.  
 
Conclusion 
In a global trial of rivaroxaban in heart failure with reduced LVEF, a protocol 
amendment requiring elevated natriuretic peptide level for inclusion increased event rates 
(including bleeding and non-CV death), but did not modify treatment effect. These data 
may inform future HF trials regarding the expected impact of NP-based inclusion criteria 




In a global trial of rivaroxaban in patients with heart failure, systolic dysfunction, and 
coronary artery disease, a protocol amendment requiring elevated natriuretic peptides for 
inclusion increased event rates for the primary endpoint (death, myocardial infarction, or 
stroke), and other endpoints including cardiovascular death, rehospitalization for heart 
failure, and bleeding. The change in inclusion criteria did not modify the neutral 
treatment effect of rivaroxaban. 
 
Translational Outlook:  
These results inform future heart failure trials regarding the expected impact of natriuretic 
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Central Illustration: Kaplan-Meier Curves for Efficacy Endpoints, According to 
Pre/Post Natriuretic Peptide Amendment Enrollment 
Hazard ratios (95% confidence interval) are from a Cox proportional hazards model with 
pre/post amendment as the only effect. P-values (two-sided) are from the log-rank test. 




Table 1: Baseline Characteristics of Patients Enrolled Before & After Natriuretic 
Peptide Amendment 
1. Data are presented as mean (standard deviation) for continuous variables, median 
(interquartile range) for highly skewed continuous variables, and number (percentage of 
total) for categorical variables.  
2. p-values (two-sided) for characteristics with continuous values are from the F-test; p-
values (two-sided) for characteristics with categorical values are from the Chi-Square 
test; p-values (two-sided) for variables with ordinal values are from the Cochran-Mantel-
Haenszel test; p-values (two-sided) for D-Dimer Troponin I and Troponin T, and 
Baseline Ejection Fraction are from Wilcoxon Test. 
3. Percentages for characteristics with categorical values and statistics summaries for 
characteristics with continuous values are based on number of subjects with non-missing 
values in each pre/post amendment group. 
4. The following characteristics have limited amount of observations: D-Dimer was from 
4107 subjects, Troponin I 604 subjects, and Troponin T 497 subjects.  
a Anemia defined as Hgb <13 g/dl in men and <12 g/dl in women.  










Age (years) 64.7 (9.7) 66.9 (10.3) <0.001 
Women 242 (21%) 908 (24%) 0.073 
Race   <0.001 
  White 1139 (99%) 2989 (77%)  
  Black or African American 6 (1%) 59 (2%)  
  Asian 0 727 (19%)  
  Other 10 (1%) 92 (2%)  
Region   <0.001 
  Eastern Europe 1032 (89%) 2192 (57%)  
  North America 15 (1%) 134 (4%)  
  Asia Pacific 0 733 (19%)  
  Latin America 45 (4%) 413 (11%)  
  Western Europe and South 
Africa 
63 (6%) 395 (10%)  
New York Heart Association 
classification 
  <0.001 
  I 16 (1%) 133 (3%)  
  II 437 (38%) 1781 (46%)  
  III 687 (60%) 1775 (46%)  
  IV 14 (1%) 178 (5%)  
Medical history    
  MI 1014 (88%) 2789 (72%) <0.001 
  Stroke 87 (8%) 366 (10%) 0.044 
  Diabetes 397 (34%) 1655 (43%) <0.001 
    Insulin use 76 (7%) 449 (12) <0.001 
  Hypertension 928 (80%) 2855 (74%) <0.001 
  Anemia a 248 (22%) 1294 (34%) <0.001 
Body mass index (kg/m
2
) 28.6 (4.9) 27.4 (5.2) <0.001 
Systolic blood pressure (mmHg) 123.6 (13.5) 122.5 (15.9) 0.035 
Diastolic blood pressure (mmHg) 74.7 (8.7) 72.9 (9.9) <0.001 
Heart rate (bpm) 69.4 (9.7) 71.7 (10.9) <0.001 
Ejection fraction (%), median 
(IQR) 
36 (30, 39) 33 (27, 38) <0.001 
eGFR (mL/min/1.73 m
2
) 71.0 (24.1) 67.2 (23.2) <0.001 
Hemoglobin (g/dL) 13.9 (1.7)  13.4 (1.8) <0.001 
Troponin I (ng/ml), median (IQR) 
(n=604) 
    0.05 (0.04, 
0.11) 
0.04 (0.02, 0.20) 0.847 
Troponin T (ng/ml), median (IQR) 
(n=497) 
    0.03 (0.01, 
0.06) 
0.04 (0.02, 0.16) 0.053 
D-dimer (ug/L), median (IQR) 
(n=4107) 
310 (190, 545) 380 (225, 695) <0.001 
Medical therapy at baseline    
Diuretic 1154 (100%) 3845 (99%) 0.033 
Beta blocker 1096 (95%) 3546 (92%) <0.001 
Angiotensin-converting enzyme 
inhibitor or angiotensin receptor 
blocker use 
1120 (97%) 3540 (92%) <0.001 
Angiotensin receptor-neprilysin 
inhibitor 
0 41 (1%) <0.001 
Mineralocorticoid receptor 
antagonist 
916 (79%) 2924 (76%) 0.009 
Nitrate  293 (25%) 715 (19) <0.001 
Hydralazine 8 (1%) 47 (1%) 0.134 
Digoxin 71 (6%) 362 (9%) <0.001 
Aspirin vs. dual antiplatelet use 
  Aspirin alone 765 (66%) 2164 (56%) 
<0.001 
  Thienopyridine alone 34 (3%) 235 (6%)  
  Dual antiplatelet therapy 350 (30%) 1396 (36%)  
  None 6 (1%) 72 (2%)  




Table 2:  Efficacy Outcomes Before & After Natriuretic Peptide Amendment 
Hazard ratios were calculated using a Cox proportional hazard model with pre/post 
amendment as the only effect. P-values are from log-rank test. CI, confidence interval; 
CV, cardiovascular; HF, heart failure. 
 Before Amendment 








(95% CI),  




11.22 15.46 1.32 (1.16, 1.50) <0.001 
  Death from any cause 9.38 12.84 1.35 (1.17, 1.55) <0.001 
  Myocardial infarction 2.04 2.46 1.08 (0.79, 1.47) 0.645 
  Stroke 1.25 1.40 0.92 (0.63, 1.37) 0.693 
CV death or 
Hospitalization for HF 
16.97 27.34 1.26 (1.13, 1.40) <0.001 
CV death 7.91 10.82 1.29 (1.11, 1.50) 0.001 
Non-CV or unknown 
death 
1.48 2.01 1.70 (1.18, 2.45) 0.004 
Hospitalization for HF 11.82 20.74 1.31 (1.15, 1.49) <0.001 
Hospitalization for non-
HF CV Cause 
10.83 15.37 1.13 (0.99, 1.30) 0.071 
All-cause mortality or 
Hospitalization for HF 
17.89 28.90 1.29 (1.16, 1.44) <0.001 
 
  
Table 3: Regional Differences in Natriuretic Peptide Amendment Effect on the 
Primary Endpoint 
Hazard ratios were calculated using a Cox proportional hazard model with pre/post 
amendment as the only effect. P-value for interaction between region and natriuretic 
peptide amendment was 0.003. Latin America and Asia Pacific were grouped together 
since no patients were enrolled in Asia Pacific before the amendment. CI, confidence 
interval. 
 
 Before Amendment After Amendment  










After vs Before  
Eastern Europe 1032 10.11 2192 13.64 1.33 (1.14-1.56) 
North America 15 16.07 134 14.26 0.92 (0.38-2.19) 
Latin America & 
Asia Pacific 
45 26.64 1146 18.09 0.63 (0.42-0.96) 
Western Europe & 
S. Africa  
63  23.26 395 19.15 0.71 (0.47-1.06) 
  
Table 4:  Safety Outcomes Before & After Natriuretic Peptide Amendment 
Hazard ratios were calculated using a Cox proportional hazard model with pre/post 
amendment as the only effect. P-values are from log-rank test. CI, confidence interval; 
Hgb, hemoglobin; HR, hazard ratio; ISTH, International Society on Thrombosis and 
Haemostasis. 
 Before Amendment 
Events / (100 pt-yr) 
(n=1155, 23%) 
After Amendment 
Events / (100 pt-yr) 
(n=3867, 77%) 
HR (95% CI), 




0.32 0.61 1.51 (0.71, 3.20) 0.280 
  Fatal bleeding  0.22 0.22 0.62 (0.24, 1.61) 0.318 
  Bleeding in critical 
space with potential 
for permanent 
disability 
0.16 0.56 3.01 (1.10, 8.26) 0.026 
ISTH major bleeding 0.86 2.10 1.71 (1.11, 2.65) 0.015 
ISTH bleeding with 
Hgb decrease ≥2g/dL 




0.35 0.76 1.29 (0.66, 2.55) 0.456 
ISTH bleeding at 
critical sites 
0.19 0.84 3.79 (1.54, 9.33) 0.002 
ISTH fatal bleeding 0.13 0.12 0.52 (0.15, 1.86) 0.308 
Bleeding requiring 
hospitalization 
0.73 1.72 1.67 (1.03, 2.69) 0.034 
  
Table 5: Treatment Effects of Rivaroxaban vs Placebo on Efficacy and Safety 
Outcomes Before & After Natriuretic Peptide Amendment 
1. Hazard ratios and 95% confidence intervals are from a Cox proportional hazards model 
with treatment assignment as the only effect. 
2. P-values (two-sided) for the interaction of treatment assignment and pre/post 
amendment are based on the Cox proportional hazard model. Covariates included in the 
Cox model are treatment assignment, pre/post amendment and interaction term for 
treatment and pre/post amendment. 
CV, cardiovascular; HF, heart failure; Hgb, hemoglobin; HR, hazard ratio; ISTH, 
International Society on Thrombosis and Haemostasis.   












1.02 (0.84, 1.24) 0.91 (0.80, 1.04) 0.355 
  Death from any cause 1.07 (0.86, 1.32) 0.95 (0.82, 1.09) 0.357 
  Myocardial infarction 0.77 (0.49, 1.23) 0.86 (0.62, 1.19) 0.724 
  Stroke 0.65 (0.36, 1.19) 0.67 (0.43, 1.05) 0.939 
CV death or 
Hospitalization for HF 
0.99 (0.84, 1.18) 1.00 (0.90, 1.11) 0.967 
CV death 1.01 (0.80, 1.27) 0.93 (0.79, 1.08) 0.545 
Non-CV or unknown 
death 
1.44 (0.83, 2.47) 1.06 (0.74, 1.51) 0.356 
Hospitalization for HF 1.01 (0.82, 1.24) 0.99 (0.87, 1.11) 0.855 
Hospitalization for non-
HF CV cause 
0.99 (0.80, 1.23) 0.93 (0.81, 1.07) 0.637 
All-cause mortality or 
hospitalization for HF 
1.04 (0.88, 1.23) 1.00 (0.91, 1.11) 0.740 
Composite primary safety 
outcome 
1.50 (0.42, 5.33) 0.65 (0.32, 1.35) 0.260 
  Fatal bleeding  1.33 (0.30, 5.96) 0.86 (0.26, 2.82) 0.650 
  Bleeding in critical 
space with potential for 
permanent disability 
0.67 (0.11, 4.01) 0.67 (0.31, 1.43) 0.998 
ISTH major bleeding 2.01 (0.90, 4.48) 1.62 (1.09, 2.39) 0.629 
ISTH bleeding with Hgb 
decrease ≥2g/dL 
3.77 (1.25, 11.35) 1.59 (0.97, 2.60) 0.161 
ISTH bleeding requiring 
transfusion ≥2 Units 
1.75 (0.51, 5.96) 1.76 (0.91, 3.40) 0.988 
ISTH bleeding at critical 
sites 
0.50 (0.09, 2.74) 1.25 (0.68, 2.30) 0.319 
ISTH fatal bleeding 0.33 (0.03, 3.19) 0.52 (0.09, 2.81) 0.762 
Bleeding requiring 
hospitalization 
2.30 (0.95, 5.58) 1.13 (0.74, 1.72) 0.157 
 
  
Supplemental Table 1: Sensitivity Analysis: Rates of Efficacy and Safety Endpoints 
Before & After Protocol Amendment Excluding Countries Enrolling Only After 
Amendment 
The eighteen countries excluded from this analysis due to enrolling only after the 
protocol amendment are: Australia, China, Japan, South Korea, Malaysia, Lithuania, 
Latvia, Slovakia, Turkey, Brazil, Denmark, France, United Kingdom, Greece, Italy, 
Portugal, Sweden, and South Africa. Hazard ratios were calculated using a Cox 
proportional hazard model with pre/post amendment as the only effect. P-values are from 
the log-rank test.  
CV, cardiovascular; HF, heart failure; Hgb, hemoglobin; HR, hazard ratio; ISTH, 
International Society on Thrombosis and Haemostasis.   
 
 Before Amendment 
Events / 100 pt-yr 
(n=1155, 32%) 
After Amendment 
Events / 100 pt-yr 
(n=2427, 68%) 
HR (95% CI) P-value 
Composite primary 
efficacy outcome 
11.22 14.19 1.23 (1.07, 1.42) 0.004 
  Death from any cause 9.38 12.16 1.30 (1.12, 1.51) <0.001 
  Myocardial infarction 2.04 2.28 1.00 (0.72, 1.41) 0.982 
  Stroke 1.25 1.15 0.79 (0.51, 1.22) 0.287 
CV death or 
Hospitalization for HF 
16.97 23.37 1.11 (0.99, 1.25) 0.072 
CV death 7.91 10.58 1.28 (1.09, 1.51) 0.003 
Non-CV or unknown 
death 
1.48 1.58 1.41 (0.93, 2.12) 0.102 
Hospitalization for HF 11.82 16.80 1.10 (0.96, 1.26) 0.188 
Hospitalization for non-
HF CV cause 
10.83 14.22 1.08 (0.93, 1.26) 0.285 
All-cause mortality or 
hospitalization for HF 
17.89 24.55 1.14 (1.01, 1.28) 0.030 
Composite primary 
safety outcome 
0.32 0.44 1.09 (0.47, 2.51) 0.845 
  Fatal bleeding  0.22 0.24 0.69 (0.25, 1.92) 0.474 
  Bleeding in critical 
space with potential for 
permanent disability 
0.16 0.38 2.10 (0.70, 6.30) 0.180 
ISTH major bleeding 0.86 1.64 1.36 (0.85, 2.19) 0.200 
ISTH bleeding with 
Hgb decrease ≥2g/dL 
0.60 1.13 1.24 (0.71, 2.17) 0.458 
ISTH bleeding requiring 
transfusion ≥2 Units 
0.35 0.50 0.91 (0.42, 1.96) 0.813 
ISTH bleeding at 
critical sites 
0.19 0.47 2.32 (0.85, 6.35) 0.095 
ISTH fatal bleeding 0.13 0.15 0.67 (0.18, 2.50) 0.547 
Bleeding requiring 
hospitalization 
0.73 1.42 1.40 (0.83, 2.34) 0.201 
 
  
Supplemental Table 2: Sensitivity Analysis: Rates of Efficacy and Safety Endpoints 
Before & After Protocol Amendment, Limited to First 2 Years of Follow-Up.  
Patients who remained at risk 2 years after randomization were censored event-free at 2 
years. Hazard ratios were calculated using a Cox proportional hazard model with pre/post 
amendment as the only effect. P-values are from the log-rank test.      
CV, cardiovascular; HF, heart failure; Hgb, hemoglobin; HR, hazard ratio; ISTH, 
International Society on Thrombosis and Haemostasis. 
 
 Before Amendment 








(95% CI),  




11.90 15.58 1.29 (1.12, 1.49) 
 
<0.001 












CV death or 
Hospitalization for HF 

















HF CV cause 




All-cause mortality or 
hospitalization for HF 






0.48 0.60 1.20 (0.56, 2.57) 0.631 
  Fatal bleeding  0.37 0.24 0.62 (0.24, 1.61) 0.318 
  Bleeding in critical 
space with potential for 
permanent disability 
0.21 0.54 2.35 (0.81, 6.79) 0.104 
ISTH major bleeding 1.28 2.11 1.49 (0.95, 2.34) 0.079 
ISTH bleeding with 
Hgb decrease ≥2g/dL 
0.96 1.34 1.27 (0.75, 2.15) 0.382 
ISTH bleeding requiring 
transfusion ≥2 Units 
0.53 0.82 1.38 (0.68, 2.77) 0.368 
ISTH bleeding at 
critical sites 
0.21 0.82 3.52 (1.25, 9.90) 0.011 
ISTH fatal bleeding 0.21 0.13 0.52 (0.15, 1.86) 0.308 
Bleeding requiring 
hospitalization 
1.01 1.71 1.50 (0.91, 2.48) 0.111 
 
 
